10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists

10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists

Independent Study Guide Notice: Independent study guide by OpenExamPrep. This educational resource is developed independently by OpenExamPrep and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.

---

Neurochemical Transmission of Acetylcholine

Acetylcholine (ACh) is the primary neurotransmitter of the parasympathetic nervous system, all autonomic preganglionic fibers (both sympathetic and parasympathetic), somatic neuromuscular junctions, and sympathetic postganglionic fibers innervating eccrine sweat glands.

Biosynthesis, Packaging & Release

1. Synthesis: Choline is transported into presynaptic cholinergic nerve terminals via a high-affinity, sodium-dependent choline transporter (CHT1) (inhibited by hemicholinium). Intracellularly, the cytosolic enzyme Choline Acetyltransferase (ChAT) catalyzes the transfer of an acetyl group from Acetyl-CoA (derived from mitochondrial metabolism) to choline, yielding acetylcholine.
2. Vesicular Storage: ACh is pumped into synaptic storage vesicles by the Vesicular Acetylcholine Transporter (VAChT), an antiporter driven by a proton gradient (inhibited experimentally by vesamicol).
3. Exocytosis & SNARE Proteins: Action potential arrival depolarizes the presynaptic terminal, triggering influx of extracellular calcium via voltage-gated N-type calcium channels. Calcium binds to synaptotagmin, triggering conformational assembly of the SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein Receptor) complex:
   • Synaptobrevin (VAMP): Vesicle-associated membrane protein.
   • Syntaxin & SNAP-25: Target plasma membrane proteins. The SNARE complex pulls the vesicle membrane into contact with the presynaptic terminal membrane, driving membrane fusion and pore opening to release ACh into the synaptic cleft.
4. Neurotoxin Disruption:
   • Botulinum Toxin (Clostridium botulinum): Cleaves specific SNARE proteins (SNAP-25 and synaptobrevin), permanently blocking ACh exocytosis at somatic neuromuscular junctions and autonomic synapses, producing flaccid paralysis.
   • Black Widow Spider Venom ($\alpha$-Latrotoxin): Inserts into the presynaptic membrane, forming calcium-permeable pores that trigger massive, uncontrolled, explosive exocytosis of ACh, causing intense muscle cramping and spasms.
5. Termination: Unlike catecholamines (which rely primarily on presynaptic reuptake), ACh signaling is terminated exclusively by rapid enzymatic degradation. Acetylcholinesterase (AChE) anchored to the post-synaptic basement membrane hydrolyzes ACh into acetate and choline within microseconds. Choline is subsequently transported back into the presynaptic terminal to replenish transmitter stores.

---

Cholinergic Receptor Taxonomy & Signaling

Cholinergic receptors are classified into two structurally and pharmacologically distinct classes: G-protein-coupled Muscarinic receptors and ligand-gated ionotropic Nicotinic receptors.

                                  Cholinergic Receptors
                                            │
               ┌────────────────────────────┴───────────────────────────┐
        Muscarinic (GPCRs)                                       Nicotinic (Ion Channels)
               │                                                        │
      ┌────────┴────────┐                                     ┌─────────┴─────────┐
      Gq                Gi                                    Nm                  Nn
   (M1, M3)            (M2)                             (Neuromuscular)       (Autonomic)
      │                 │                                     │                   │
  PLC → IP3/DAG      ↓ Adenylyl Cyclase                 Motor Endplate        Autonomic Ganglia
  ↑ Intracellular    ↓ cAMP                             Na+/K+ Influx         Adrenal Medulla
  Calcium            SA/AV Node Inhibition              Muscle Contraction    Epi/NE Secretion

Muscarinic Receptors ($M_1, M_2, M_3$)

Nicotinic Receptors ($N_m, N_n$)

Nicotinic receptors are pentameric, ligand-gated ion channels composed of five transmembrane glycoprotein subunits arranged symmetrically around a central aqueous ion pore:

• $N_m$ (Muscle Type): Situated exclusively at the skeletal muscle motor endplate (composed of $(\alpha_1)_2\beta_1\gamma\delta$ or $(\alpha_1)_2\beta_1\epsilon\delta$). Binding of two ACh molecules induces channel opening, driving rapid influx of extracellular $Na^+$ and minor efflux of $K^+$. This generates an Endplate Potential (EPP), depolarizing the sarcolemma to fire muscle action potentials and initiate excitation-contraction coupling.
• $N_n$ (Neuronal Type): Located on postganglionic neurons in all autonomic ganglia (sympathetic and parasympathetic), within the adrenal medulla, and in the central nervous system (composed of $\alpha$ and $\beta$ subunit variations). Activation mediates ganglionic transmission and triggers catecholamine (epinephrine and norepinephrine) secretion directly into the bloodstream from chromaffin cells.

---

Cholinomimetic Agonists: Direct & Indirect

Direct Muscarinic Agonists

Indirect-Acting Agonists (Acetylcholinesterase Inhibitors)

AChE inhibitors prevent the breakdown of endogenous ACh, thereby elevating synaptic ACh concentrations and amplifying stimulation at both muscarinic ($M_1 - M_3$) and nicotinic ($N_m, N_n$) receptors.

---

Organophosphate Poisoning & The Cholinergic Crisis

Organophosphate Toxicology & Chemical "Aging"

Organophosphates (e.g., parathion, malathion, echothiophate, and chemical nerve agents including sarin, soman, and tabun) are lipid-soluble compounds that bind covalently to the serine hydroxyl group in the catalytic triad of acetylcholinesterase, forming an exceptionally stable, irreversible phosphorylated enzyme complex.

• Chemical Aging: Over subsequent minutes to hours, the phosphorylated enzyme undergoes a spontaneous dealkylation reaction termed "aging". Once aging occurs, the chemical bond is permanently cleaved and stabilized, rendering the enzyme completely refractory to chemical reactivation. Pharmacotherapy must be initiated rapidly prior to aging.

Clinical Manifestations: The DUMBBELLS Toxidrome

Accumulation of acetylcholine at all cholinergic synapses produces widespread crisis:

$\textbf{DUMBBELLS Mnemonic for Muscarinic Hyperstimulation:}$

• D: Diarrhea and abdominal cramping
• U: Urination (detrusor contraction, sphincter relaxation)
• M: Miosis (pinpoint pupils via pupillary sphincter contraction)
• B: Bradycardia (M2 SA nodal inhibition) & Bronchorrhea / Bronchospasm (M3 airway flooding and constriction — primary cause of mortality)
• E: Emesis
• L: Lacrimation
• L: Lethargy and central seizures
• S: Salivation and Sweating (sympathetic cholinergic)

In addition to muscarinic signs, hyperstimulation at Nicotinic ($N_m$) receptors produces muscle fasciculations, cramping, and subsequent depolarization neuromuscular blockade leading to flaccid diaphragmatic paralysis and respiratory arrest.

Definitive Antidote Protocol

Muscarinic Antagonists (Anticholinergics)

Muscarinic receptor antagonists competitively inhibit acetylcholine binding at postganglionic parasympathetic neuroeffector junctions.

High-Yield Antimuscarinic Drugs

• Atropine: Prototypic non-selective competitive muscarinic blocker; tertiary amine crossing the BBB. First-line pharmacotherapy for symptomatic sinus bradycardia, organophosphate intoxication, and intraoperative antisialagogue to reduce airway secretions.
• Scopolamine: Tertiary amine with pronounced CNS penetration; acts on vestibular muscarinic pathways to prevent and treat motion sickness (transdermal patch) and postoperative nausea.
• Ipratropium & Tiotropium: Inhaled quaternary ammonium antimuscarinics (minimal systemic absorption); block bronchial $M_3$ receptors to promote bronchodilation and reduce mucous secretions. First-line therapy for Chronic Obstructive Pulmonary Disease (COPD) and adjunctive in acute asthma.
• Oxybutynin, Tolterodine, Solifenacin: Antimuscarinics with selectivity for bladder $M_3$ receptors; relax the detrusor muscle to treat urgency urinary incontinence and overactive bladder.
• Glycopyrrolate: Quaternary amine antimuscarinic; does not cross the blood-brain barrier. Used perioperatively to reduce salivary and respiratory secretions and co-administered with neostigmine during neuromuscular block reversal to prevent muscarinic bradycardia without inducing central anticholinergic delirium.
• Benztropine & Trihexyphenidyl: Centrally active tertiary antimuscarinics; cross the BBB to restore the dopaminergic-cholinergic balance in the striatum. Used in Parkinson disease and for the prevention and reversal of acute drug-induced extrapyramidal symptoms (acute dystonia) caused by antipsychotics.

Anticholinergic Toxidrome

Overdose or adverse accumulation of antimuscarinic agents (including atropine, tricyclic antidepressants, first-generation antihistamines, and belladonna alkaloids) triggers a classic clinical toxidrome:

$\textbf{Anticholinergic Toxidrome Classic Mnemonic:}$

• "Blind as a bat": Mydriasis (pupillary dilation via unopposed sympathetic $\alpha_1$) and cycloplegia (ciliary muscle paralysis, loss of near accommodation).
• "Mad as a hatter": Central muscarinic blockade causing confusion, delirium, acute agitation, visual hallucinations, and encephalopathy.
• "Red as a beet": Cutaneous vasodilation producing diffuse facial and upper body flushing (compensatory cutaneous shunting to dissipate heat).
• "Hot as a hare": Severe hyperthermia resulting from complete shutdown of eccrine sweat glands (loss of sympathetic cholinergic $M_3$ diaphoresis).
• "Dry as a bone": Total xerostomia, cracked lips, and anhidrosis (dry skin).
• "Full as a flask": Severe urinary retention (detrusor relaxation and internal sphincter closure) and severe constipation / paralytic ileus.
• Cardiovascular: Sinus tachycardia due to blockade of vagal $M_2$ receptors on the SA node.

---

Neuromuscular Blocking Agents (NMBs)

Neuromuscular blocking drugs are administered during surgical induction to achieve skeletal muscle relaxation and facilitate endotracheal intubation. They act specifically at the $N_m$ nicotinic receptors of the skeletal motor endplate.

Depolarizing NMB: Succinylcholine

• Mechanism of Action: Succinylcholine is composed of two conjoined acetylcholine molecules. It binds to the $N_m$ nicotinic receptor and stimulates it continuously, acting as a non-metabolized agonist:
  • Phase I Block (Depolarizing Phase): Produces initial, disorganized motor unit depolarizations visible clinically as muscle fasciculations. Because succinylcholine is not degraded by synaptic AChE, the motor endplate remains persistently depolarized ($> -55\text{ mV}$). The perijunctional voltage-gated sodium channels enter a prolonged, locked inactivated state, preventing propagation of further action potentials and resulting in flaccid paralysis. Phase I block is augmented, not reversed, by acetylcholinesterase inhibitors like neostigmine!
  • Phase II Block (Desensitization Phase): With prolonged exposure or continuous infusion, the endplate membrane eventually repolarizes, but the nicotinic receptors become desensitized and refractory to acetylcholine. The characteristics of Phase II block resemble those of a non-depolarizing blockade and can theoretically be reversed by AChE inhibitors.
• Metabolism: Succinylcholine is cleared extremely rapidly from systemic circulation by Plasma Pseudocholinesterase (Butyrylcholinesterase), yielding a brief clinical duration of $5 - 10\text{ minutes}$.

• Adverse Effects of Succinylcholine:
  • Hyperkalemia: Persistent open-state $N_m$ channels allow sustained intracellular $K^+$ efflux into systemic circulation, normally raising serum potassium by $0.5\text{ mEq/L}$. However, in patients with denervation injuries (spinal cord transection, stroke), extensive burn injuries, severe crush trauma, or muscular dystrophies, widespread upregulation of extrajunctional nicotinic receptors occurs across the entire muscle sarcolemma. Administration of succinylcholine in these patients triggers massive, catastrophic hyperkalemia leading to ventricular fibrillation and cardiac arrest.
  • Increased Intraocular and Intragastric Pressure: Fasciculations can transiently elevate pressure, risking extrusion of ocular contents in open-globe trauma.

Malignant Hyperthermia

Malignant Hyperthermia (MH) is a life-threatening, pharmacogenetic hypermetabolic crisis triggered when susceptible individuals are exposed to succinylcholine or volatile halogenated inhalational anesthetics (e.g., halothane, isoflurane, sevoflurane, desflurane).

• Pathophysiology: Caused by an autosomal dominant mutation in the Ryanodine Receptor Gene (RYR1) (or less commonly CACNA1S), which encodes the calcium release channel of the sarcoplasmic reticulum in skeletal muscle. Triggering agents cause uncontrolled, sustained, massive efflux of stored calcium from the sarcoplasmic reticulum into the myoplasm. Unchecked calcium activates myosin ATPase, stimulating continuous excitation-contraction coupling, sustained muscle rigidity, and catastrophic depletion of cellular ATP.
• Clinical Presentation: Earliest signs include unexplained tachycardia, acute tachypnea, and rapidly rising end-tidal $CO_2$ ($ETCO_2$) refractory to hyperventilation. Patients develop masseter muscle spasm / rigidity, generalized skeletal muscle rigidity, severe metabolic and respiratory acidosis, rhabdomyolysis (hyperkalemia, hyperphosphatemia, myoglobinuria risking acute renal failure), and dramatic late hyperthermia ($> 40°\text{C} / 104°\text{F}$).
• Treatment:
  1. Immediately discontinue all volatile anesthetics and succinylcholine; hyperventilate with $100\% O_2$.
  2. Administer intravenous Dantrolene ($2.5\text{ mg/kg}$ IV push, repeated as necessary). Mechanism of Dantrolene: Directly binds to the ryanodine receptor (RYR1) on the sarcoplasmic reticulum, blocking channel opening and preventing further calcium efflux into the myoplasm, halting the hypermetabolic cascade.
  3. Active external and internal cooling, intravenous sodium bicarbonate for severe acidosis, and aggressive diuresis with IV fluids to protect against myoglobinuric acute tubular necrosis.

Non-Depolarizing NMBs & Pharmacologic Reversal

Non-depolarizing agents act as competitive antagonists at the $N_m$ receptor. They prevent acetylcholine from binding, preventing depolarization of the motor endplate. Unlike succinylcholine, they cause no muscle fasciculations.

Reversal of Non-Depolarizing Blockade

At the conclusion of surgical procedures, non-depolarizing blockade must be actively reversed:

1. Acetylcholinesterase Inhibitors (Neostigmine): Inhibits AChE, raising synaptic ACh levels to competitively displace the non-depolarizing blocker from the $N_m$ receptor. To prevent neostigmine from stimulating muscarinic receptors and inducing severe bradycardia, bronchospasm, and salivation, it must always be co-administered with a muscarinic antagonist:
   • Neostigmine + Glycopyrrolate (matched onset profiles; glycopyrrolate does not cross BBB, preventing central delirium).
2. Sugammadex: A modified $\gamma$-cyclodextrin macrocycle that reverses rocuronium and vecuronium. Sugammadex does not alter ACh concentrations; instead, it acts as a chemical chelator that encapsulates rocuronium molecules in plasma in a $1:1$ stoichiometric complex, rendering them inactive and driving diffusion away from neuromuscular junctions. Provides ultra-rapid reversal without cholinergic or anticholinergic adverse effects.